Cancer vaccines: between the idea and the reality

By O. Finn. Nature reviews. Immunology, 2003

648 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Dendritic cells as therapeutic vaccines against cancer (2005, background): “Yet, the most attractive strategy is vaccination, which is expected to induce both therapeutic T-cell immunity (in the form of tumour-specific effector T cells) and protective T-cell immunity (in the form of tumour-specific memory T cells that can control tumour relapse”
Regulatory T cells, tumour immunity and immunotherapy (2006, background): “One reason for this is that immunosuppressive mechanisms predominate in patients with advanced cance”
Mechanisms of immune evasion by tumors. (2006, background): “Translating these observations to the clinical setting is not straightforward but suggests that immunotherapy approaches may prove most efficacious in the setting of minimal residual disease (Finn, 2003).”
Cancer immunotherapy via dendritic cells (2012, neutral): “These, however, have potential shortcomings: the range of high-avidity clones might be depleted through negative selectio”
Myeloid-derived Suppressor Cells Inhibit T Cell Activation by Depleting Cystine and Cysteine (2009, background): “70 Cancer Res; 70(1) January 1, 2010 Cancer Research l”